Investment
Features
FeesSafety
Academy
More
Pluang+

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

Others
14 Oct 2026
Na
View Source
Bullish
CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, continuously probing for vulnerabilities to help organizations identify and fix security gaps before actual attackers exploit them. The technology aims to transform offensive security from periodic testing into a constant, scalable process, enhancing defense capabilities amid evolving cyber threats. CodeWall is already working with major banks and consulting firms and plans to expand its platform and teams with the new funding.

CodeWall's $4M funding news is presented alongside Technology-sector market data from Pluang. For readers following Technology stocks, here is Pluang's market snapshot as of Oct 14, 2026 18:03 WIB: out of 150 priced stocks, 55 rose and 86 fell. Notable movers include Marqeta Inc at USD 19.35 with a 1-day change of +4.26%, Hewlett Packard Enterprise Co at USD 66.00 down 4.07%, and NetApp Inc. at USD 230.84 down 3.37%.

More News

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...

Market News
Bullish
1 hour ago
FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...

Market News
Bullish
1 hour ago
DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...

Company Fundamentals
Neutral
1 hour ago
Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...

Market News
Bullish
2 hours ago
Global anthracite market to reach $16.8B by 2035, driven by steel and water filtration demand.

Global anthracite market to reach $16.8B by 2035, driven by steel and water filtration demand.

The global anthracite market, valued at $11.9 billion in 2025, is projected to grow to $16.8 billion by 2035 with a 3.5% CAGR. Growth is fueled by rising demand in steel production, water filtration, and advanced industrial uses due to anthracite's h...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App